Vancomycin biosynthesis, clinical uses & adverse effects
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
New York
Nova Science Publishers
2014
|
| Schriftenreihe: | Pharmacology - Research, Safety Testing and Regulation
|
| Schlagworte: | |
| Online-Zugang: | DE-91 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Inhaltsangabe:
- There have been news reports with the tales of many community acquired bacterial infections that lead to serious hospitalization. The last resort drug for these infections is vancomycin; an FDA approved glycopeptide antibiotic for the treatment of several bacterial infections, including infections caused by susceptible staphylococcus, streptococcus, enterococcus, and diphtheroid organisms. Around the world in 1997, initial reports of reduced vancomycin susceptibility in clinical isolates of staphylococcus aureus generated significant concern in the medical community. There has been uncertainty
- VANCOMYCIN: BIOSYNTHESIS, CLINICAL USES AND ADVERSE EFFECTS; VANCOMYCIN: BIOSYNTHESIS, CLINICAL USES AND ADVERSE EFFECTS; Library of Congress Cataloging-in-Publication Data; Contents; Preface; Chapter 1: Pharmacodynamic Dosing of Vancomycin: Concepts and Clinical Evidence; Abstract; A Brief History of Vancomycin; Vancomycin Pharmacokinetics and Pharmacodynamics; Vancomycin: A Consensus Review; Clinical Benefit from Higher Trough Goals; Higher Trough Goals: More Harm than Good?; AUC/MIC Ratio or Trough Concentrations: Where Should the Focus Be?
- Individualization of Doses: Calculating Doses, Estimating Troughs, and Estimating AUCConclusion; References; Chapter 2: Comparative and Functional Genomics as Tools for Understanding Vancomycin Resistance in Bacteria; Abstract; Introduction; Comparative Genomics and Vancomycin Resistance; Functional Genomics and Vancomycin Resistance; References; Chapter 3: Vancomycin: Use, Dosing and Therapeutic Drug Monitoring; Abstract; Introduction; Indications and Efficacy; Toxicity; Drug Interactions; Analytical Methods; Pharmacokinetics and Pharmacodynamics; Dosing; Therapeutic Drug Monitoring
- ConclusionAcknowledgments; References; Chapter 4: Clinical Use of Vancomycinin Cardiovascular Homograft Banking; Abstract; Introduction; Bioburden Reduction of Homografts; Emerging Importance of Vancomycin in Tissue Banking; Benefits and Concerns of Residual Antibiotics; Conclusion; References; Chapter 5: Common and Uncommon Adverse Effects of Vancomycin; Abstract; Introduction; Vancomycin-related Nephrotoxicity; Vancomycin-related Skin Reactions; Vancomycin-related Ototoxicity; OTHER ADVERSE EFFECTS; Conclusion; Acknowledgments; REFERENCES
- Chapter 6: Clinical Use of Vancomycin in Methicillin-Resistant S. Aureus or Coagulase-Negative Staphylococci Bacteremia, Catheter-Related Bacteremia and EndocarditisAbstract; Introduction; Methicillin-Resistant Staphylococci Primary Bacteremia; Methicillin-Resistant Staphylococci Catheter-Related Bacteremia; Methicillin-Resistant Staphylococci Endocarditis; Conclusion; References; Chapter 7: Clinical Use of Vancomycin in MRSA Ventilator-Associated Pneumonia; Abstract; Introduction; Epidemiology; Risk Factors; Morbidity/Mortality/Cost; Treatment; Conclusion; References
- Chapter 8: Clinical Use of Vancomycin in Methicillin-Resistant Staphylococci Bone and Joint InfectionAbstract; Introduction; Intermittent or Continuous Infusion of Vancomycin; Use of Vancomycin as Definite Therapy; Conclusion; Acknowledgments; References; Index